More than 400 companies in the ASX All Ords fell yesterday, with some hitting new 52-week lows.

Brokers say these ASX All Ords shares are good buys in today's market.

Here are their 12-month share price targets on each stock.

Objective Corporation Ltd (ASX: OCL)

The Objective Corporation share price fell to a 52-week low of $11.68 on Thursday.

The ASX All Ords tech share is down 29% in the year to date (YTD), and down 22% over the past 12 months.

Following the stock's recent fall, Morgans upgraded its rating from accumulate to buy.

However, the broker reduced its 12-month price target from $20 to $16.70.

Morgans said:

We see tailwinds remaining supportive of OCL's long-term growth momentum.

Generation Development Group Ltd (ASX: GDG)

The Generation Development Group share price fell to a 52-week low of $3.71 yesterday.

The ASX All Ords financial share is down 35% YTD, and down 21% over the past 12 months.

Morgans recently retained its buy rating but reduced its 12-month price target from $7.97 to $6.66.

The broker said:

We believe GDG has a great story, and management has executed well over time.

Jumbo Interactive Ltd (ASX: JIN)

The Jumbo Interactive share price dropped to a 52-week trough of $7.66 yesterday.

This ASX All Ords gaming share has fallen 32% YTD, and is down 25% over the past 12 months.

Jarden has a buy rating on Jumbo Interactive shares with a price target of $12.70.

Cleanaway Waste Management Ltd (ASX: CWY)

The Cleanaway Waste Management share price fell to a 52-week low of $2.31 on Thursday.

The ASX All Ords industrials share has fallen 11% YTD, and dropped 9% over 12 months.

Morgans has a buy rating with a 12-month price target of $3.11.

The broker commented:

1H26 was a mixed bag, with a minor bottom-of-the-range EBIT guidance upgrade.

Next catalyst is the investor strategy day planned for 21 April.

Earnings forecast adjustments are minimal, cashflow downgrades more material.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a 52-week low of $20.50 on Thursday.

The ASX All Ords healthcare share has deteriorated 8% YTD and 20% over the past year.

Macquarie has an outperform rating on Sonic Healthcare with a price target of $27.50.

Saluda Medical Inc (ASX: SLD)

Fellow ASX All Ords healthcare share, Saluda Medical, dropped to a 52-week low of 80 cents yesterday.

The Saluda Medical share price has tumbled 42% YTD, and is down 35% over 12 months.

Morgans has a speculative buy rating with a 12-month price target of $3.07.

The broker said:

1H26 showed solid revenue momentum, improving margins, and continued expansion of the US sales force, supporting confidence in a stronger 2H.

Reiteration of FY26 revenue guidance (US$85m) added further comfort and now expects to exceed IPO metrics for gross margin, adjusted EBITDA and cash burn.

The post 6 ASX All Ords shares at 52-week lows: Experts say buy appeared first on The Motley Fool Australia.

So far in 2026, its share price is down 24%. 

However it appears the tide could be turning after the company posted its H1FY26 result yesterday. 

The stock price soared 9.6% higher following the release. 

Here's what the company reported. 

H1 FY26 Results

Saluda Medical Inc is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. 

It is currently a single-product company, centred around its differentiated SCS product called the 'Evoke System'. 

Yesterday the ASX healthcare stock reported: 

• International revenue of US$11.0 million (+27% vs pcp)
• Acceleration in global revenue growth (+ 17% vs prior corresponding period (pcp) to US$39.4 million), driven by increase in US trained sales reps and active physicians
• US implanted patient growth of 17% vs pcp, driven by an increase in active implanting physicians. 

Commenting on the release, Saluda's Chief Executive Officer, Barry Regan, said: 

We are pleased with the momentum within the first six months of FY26. We saw continued growth in the active implanting physician base and remain confident in our ability to build the size and quality of our sales force as planned heading into the new calendar year. 

Our team continues to be focused on execution and driving the organisation in line with our growth strategy. Our first half performance gave us the confidence to previously increase our FY26 revenue guidance. 

Additionally, we expect to improve on our other key FY26 financial metrics of gross margin, adjusted EBITDA, and cash used in operations. 

Buy recommendation for this ASX healthcare stock

Following the result, the team at Bell Potter reiterated its buy recommendation on the ASX healthcare stock. 

In a report yesterday, the broker said the stock is trading at undemanding multiples of <1x EV/Revenue and ~1.5x Price/Revenue based on its FY27 forecast, with expected growth of +25% in 2H26, mostly driven by the US. 

Management have so far demonstrated strong execution slightly ahead of the plans laid out at the time of the IPO.

Bell Potter has a 12 month price target of $2.70 on this ASX healthcare stock. 

From yesterday's closing price of $1.085, this indicates a potential upside of 148.8%. 

Bell Potter isn't the only broker with a positive outlook.

Earlier this month, Morgans put a speculative buy rating and $3.07 price target on its shares.

That indicates a potential upside of 182%. 

The post Is this ASX healthcare stock a buy, hold or sell after jumping 10% on earnings results? appeared first on The Motley Fool Australia.

But which small caps are buys? Let's take a look at three that Morgans is recommending to clients:

Meeka Metals Ltd (ASX: MEK)

This gold miner could be a small-cap ASX share to buy according to Morgans. In response to the company's quarterly update, the broker has retained their buy rating and 33 cents price target on its shares.

It was relatively pleased with the miner's performance during the quarter. It said:

MEK delivered its 2Q26 operating result as the Murchison Gold Project continues to ramp up. Gold production increased 28% quarter on quarter to 9.1koz Au and was in-line with MorgansF of 9.3koz Au. Ounce production was underpinned by a mill head grade of 3.3g/t Au, ~10% above MorgansF assumptions; however, this grade outperformance is partially offsetting lower-than-expected throughput.

Looking ahead, improvements in mill throughput, driven by underground production, remain key to maintaining alignment with PFS forecasts We maintain our BUY rating, price target A$0.33ps and update our precious metals price deck.

Neurizon Therapeutics Ltd (ASX: NUZ)

Another small-cap ASX share that gets a thumbs up from Morgans is Neurizon. It has put a speculative buy rating on its shares with a reduced price target of 28 cents.

The broker believes that with major risks cleared, now is a great time to be jumping on board with this clinical-stage biotech company. This is especially the case given how there is a condensed catalyst runway ahead of it. It said:

Following FDA clearance, the imminent start of the Ph2/3 trial and the removal of the funding overhang providing full visibility through the pivotal program, NUZ now offers one of the cleanest entry points seen in the past 18 months, with major risks cleared and a condensed catalyst runway ahead.

Recent M&A activity underscores the scarcity value of ALS assets and provides a meaningful valuation anchor for NUZ if its clinical program delivers. Post recent capital raises, we update for the new share issuances which drive a reduction in our target price to A$0.28 from A$0.39, although we maintain our Speculative Buy rating, noting the high risk / high reward proposition.

Saluda Medical Inc (ASX: SLD)

This commercial-stage medical device company could also be a small-cap ASX share to buy according to Morgans. It has put a speculative buy rating and $3.07 price target on its shares.

It was pleased with the company's second quarter update and management revenue guidance upgrade for FY 2026. The broker said:

2Q activity report debut did not disappoint, highlighting accelerating US commercial momentum, cost actions to reduce future operating expenses and upgraded FY26 revenue guidance. Revenue growth jumped 15% QoQ, supported by rising implanted patient volumes, and continued expansion of both sales reps and implanting physicians, while cash outflow fell 14% QoQ on a lower fixed cost base supportive of operating leverage.

We believe management's decision to lift FY26 revenue guidance c4% at this early-stage post-IPO reflects improving visibility on sales execution and demand trends, reinforcing confidence in a stronger 2H performance. We update FY26 forecasts in line with guidance, with our DCF-based TP unchanged at A$3.07. SPECULATIVE BUY maintained.

The post Morgans names 3 exciting small cap ASX stocks to buy now appeared first on The Motley Fool Australia.

It is a commercial-stage medical device company commercialising spinal cord stimulation (SCS) therapy. 

Saluda is currently a single product company, centred around its differentiated SCS product called the 'Evoke System'.

It is designed for the treatment of patients with chronic pain of the trunk and/or limbs.

A bumpy ride 

Since initially listing in December last year, this small-cap ASX healthcare stock has experienced volatility.

After opening at $1.27, the company saw its share price rocket 20% higher within the first week of trading. 

However after topping out at $1.54, it has tumbled more than 26%. 

This included a fall of more than 5% yesterday.

It now sits close to an all-time low at $1.13. 

It's important to acknowledge that small-cap stocks can often experience increased volatility. 

First update since December 

Yesterday, the company released its first financial update since its IPO last December. 

The company reported 1H26 revenue of $39.4m (+17% on pcp). 

In a report from Bell Potter yesterday, the broker said the biggest positive was strong Q2 sales of $15.4m in the US (+17% on pcp and +19% qoq) driven by a greater number of physicians utilising the Evoke System. 

International sales are a smaller contribution compared to the key US market but also increased during 1H26 to $11.0m (+26% on pcp).

Bell Potter said this reflected strong execution on commercial targets as the company beat its 1H26 revenue forecast. This resulted in an upgraded FY26 revenue guidance by 4% to $85m. 

Buy recommendation for this ASX healthcare stock

The broker increased FY26 forecasts in line with the updated guidance while leaving FY27 and FY28 effectively unchanged. 

Bell Potter said penetration into the US physician base is deepening and total volumes will benefit from the ongoing expansion and training of Saluda's US sales force, which is proceeding at good pace. 

Updated forecasts imply 2H26 global revenue growth of +25% on the pcp, with the most relevant focus being US sales, which we now expect to reach $34.2m in 2H26 at a growth rate of +37% on the pcp.

The broker has retained its speculative buy recommendation on this ASX healthcare stock and slightly decreased its price target to $2.70 (previously $2.80). 

From yesterday's closing price of $1.13, this indicates an upside of 138.94%. 

We maintain our BUY (speculative) recommendation and look forward to accelerating market share capture of the crucial US market over the coming reporting periods.

The post Is this ASX healthcare stock a buy after yesterday's 5% drop? appeared first on The Motley Fool Australia.

Small-cap stocks may appeal to investors as they can have significant growth potential compared to more established, blue-chip shares.

However it's important to understand they can have significant volatility, as many of these small companies can be pre-profit, relying on funding, clinical trials etc. 

With that being said, here are two that have buy recommendations from the team at Bell Potter. 

Saluda Medical (ASX: SLD)

Saluda Medical is a commercial-stage medical device company commercialising spinal cord stimulation (SCS) therapy globally.

According to yesterday's report, Saluda Medical is currently a single-product company, centred around its differentiated SCS product called the 'Evoke System'. 

The company has been commercialising the Evoke System for ~3 years in the US, and ~5 years in Europe and Australia, for the treatment of patients with chronic pain of the trunk and/or limbs.

Bell Potter has initiated coverage on this small-cap stock with a buy recommendation (speculative) for several key reasons: 

• Saluda's patented closed-loop system delivers more consistent and durable pain relief than conventional devices. In its Phase 3 trial, no patients had devices removed due to lack of efficacy over three years.
• IPO funds will expand the US sales force to >150 reps by FY26, supporting broader geographic coverage, deeper physician adoption, and a paddle lead launch in FY27 targeting neurosurgeons.
• US revenue exceeded US$50m in under three years (~2% of the US$2.2b SCS market). Bell Potter forecasts revenue approaching US$290m by FY29, with US market share rising to ~9%.
• It has an attractive valuation trading at ~1.7x FY26 EV/Revenue (3.0x P/S), a discount to peers (~5x). Successful execution and EBITDA breakeven by FY29 could support meaningful re-rating.

Based on this guidance, Bell Potter has a price target of $2.80 on this ASX small-cap stock. 

That indicates an upside of more than 88% from yesterday's closing price of $1.485. 

American Rare Earths Ltd (ASX: ARR)

American Rare Earths is an Australian exploration company targeting the discovery and development of strategic technology mineral resources in the USA and Australia.

The team at Bell Potter have initiated a buy recommendation (speculative) on this ASX small-cap stock. 

In yesterday's report, the broker said the company is uniquely positioned to capitalise on the US' Strategic focus to reduce reliance on a China dominated rare earth supply chain. 

The Cowboy State Mine offers a long-term solution within the US to decouple from external sources of rare earths, particularly heavy rare earths DyTb.

Essentially, Cowboy State Mine could help the US secure domestic supply of dysprosium and terbium, reducing reliance on China for these critical minerals.

Bell Potter initiated its coverage with a price target of $0.65. 

This indicates an upside of more than 94% from yesterday's closing price of $0.335.

The post Top broker just initiated coverage on two ASX small-cap stocks with a buy recommendation appeared first on The Motley Fool Australia.